Supernus Pharmaceuticals will acquire Sage Therapeutics through a tender offer totalling approximately $795 million.  The transaction will provide Supernus with Zurzuvae (zuranolone) capsules CIV, the only US Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression.  Through a collaboration agreement with Biogen, Supernus will report collaboration revenue that […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!